New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans

Groundbreaking MRI study links brainstem damage to long COVID symptoms in survivors.

Study: Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations. Image Credit: Silver Place/Shutterstock.comStudy: Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations. Image Credit: Silver Place/Shutterstock.com

A recent study published in Brain performed ultrahigh field quantitative susceptibility mapping (QSM) of the brainstem in coronavirus disease 2019 (COVID-19) survivors post-hospitalization.

Introduction

Neuroradiological changes have been reported in hospitalized COVID-19 patients. Cerebral microhemorrhages, white matter hyperintensities, and encephalopathy are the most common acute findings. Moreover, brainstem involvement, with inflammatory responses and neurodegeneration, has been observed in COVID-19.

These brainstem abnormalities have been proposed as a mechanism for post-acute COVID-19 syndrome (PACS). Nevertheless, conventional 3 Tesla (3T) magnetic resonance imaging (MRI) has not shown consistent brainstem abnormalities at follow-up. As such, advanced MRI techniques, e.g., QSM, have the potential to identify more subtle changes.

QSM can detect chronic inflammation in multiple sclerosis, cerebral microbleeds, and increases in iron deposition in the midbrain and basal ganglia.

Moreover, ultrahigh-field QSM (≥ 7T) enhances susceptibility contrast in subcortical and cortical tissues, enabling the detection of microstructural alterations.

About the study

In the present study, researchers investigated brainstem abnormalities by subregions using 7T QSM in COVID-19. COVID-19 patients discharged after hospitalization were recruited for 7T MRI in the United Kingdom (UK). Eligible participants had confirmed COVID-19, with no contraindications to 7T MRI and a pre-COVID-19 history of psychiatric or neurological disorders.

The lowest platelet levels and the peak D-dimer and C-reactive protein (CRP) levels during hospitalization were recorded.

During the follow-up, mental health was assessed using the patient health questionnaire (PHQ)-9 and generalized anxiety disorder (GAD)-7, and functional recovery was evaluated using the modified Rankin scale (mRS). Healthy controls (HCs) also underwent a 7T MRI.

Two control subgroups (HC1 and HC2) were scanned before December 2019, and one subgroup (HC3) underwent MRI during the pandemic. Brainstem regions of interest (ROIs) included the midbrain, medulla, superior cerebellar peduncle (SCP), and pons.

Mean susceptibility per ROI was extracted and used for subsequent analyses. In addition, voxel-wise analyses were undertaken to improve resolution.

Findings

Overall, 30 COVID-19 patients and 51 HCs were enrolled. The two groups did not significantly differ in age; however, the control group had more males than females.

The median time between hospitalization and MRI acquisition was 199 days for the COVID-19 group. The regional mean susceptibility increased in the brainstem of the COVID-19 group compared to HCs.

This increase was localized in the medulla and pons; however, the midbrain also showed a weak significant effect.

No group differences were observed in the SCP. Voxel-wise analyses identified two significant clusters in the medulla, with a substantial increase in susceptibility in the COVID-19 group. These clusters partially overlapped regions associated with body homeostasis and respiratory function.

Additional clusters were identified in the midbrain and pons at a less stringent threshold. The mean susceptibility values extracted from the two medullary clusters were positively associated with the peak CRP detected during hospitalization and weakly associated with clinical disease severity and length of hospital stay. No significant trends were observed for other variables.

Conclusions

The findings provide evidence of mid- to long-term microstructural abnormalities in the brain after COVID-19 hospitalization. Results demonstrate magnetic resonance susceptibility abnormalities in several regions in the midbrain, pons, and medulla at a median of 6.5 months following hospitalization. These differences were consistent with neuroinflammatory responses.

The fact that the affected regions are the sites of respiratory pathways highlights that lingering symptoms might be an indirect effect of brainstem inflammatory injury after COVID-19.

These effects were more pronounced in those with severe COVID-19 and were age- and gender-independent. Voxel-wise analyses revealed clusters with increased susceptibility in the raphe obscurus, raphe pallidus, and inferior medullary reticular formation nuclei in the COVID-19 group relative to HCs.

Fatigue, dyspnea, chest pain, and cough are the common symptoms post-COVID-19. Brainstem abnormalities may exacerbate or predispose to such symptoms beyond peripheral organ damage. The researchers posit that brainstem insult ensues after COVID-19 in hospitalized patients.

In sum, the study findings indicate that the brainstem is susceptible to long-term COVID-19 effects, with persistent changes evident even months post-hospitalization.

These changes were particularly pronounced in patients with increased clinical severity, worse functional outcomes, protracted hospital stays, and elevated inflammatory responses.

Ultrahigh field QSM was sensitive to these pathological changes, which could not be detected at standard clinical field strengths. As such, it could be a valuable tool to investigate the long-term impact of COVID-19 and other diseases.

Journal reference:
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2024, October 10). New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans. News-Medical. Retrieved on October 10, 2024 from https://www.news-medical.net/news/20241010/New-study-reveals-long-term-brainstem-damage-in-COVID-19-survivors-using-advanced-MRI-scans.aspx.

  • MLA

    Sai Lomte, Tarun. "New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans". News-Medical. 10 October 2024. <https://www.news-medical.net/news/20241010/New-study-reveals-long-term-brainstem-damage-in-COVID-19-survivors-using-advanced-MRI-scans.aspx>.

  • Chicago

    Sai Lomte, Tarun. "New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans". News-Medical. https://www.news-medical.net/news/20241010/New-study-reveals-long-term-brainstem-damage-in-COVID-19-survivors-using-advanced-MRI-scans.aspx. (accessed October 10, 2024).

  • Harvard

    Sai Lomte, Tarun. 2024. New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans. News-Medical, viewed 10 October 2024, https://www.news-medical.net/news/20241010/New-study-reveals-long-term-brainstem-damage-in-COVID-19-survivors-using-advanced-MRI-scans.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Long COVID affects 38% of emergency patients with persistent symptoms